ESTRADIOL
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Estradiol acts by binding to estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and cellular effects. It influences reproductive tissues, bone density, cardiovascular system, and central nervous system.
| Metabolism | Hepatic metabolism primarily via CYP3A4 and CYP1A2 isoenzymes; undergoes oxidation and glucuronidation. Metabolites include estrone and estriol; excreted in urine (conjugated forms). |
| Excretion | Renal (50-80% as glucuronide and sulfate conjugates), biliary/fecal (10-30%), <5% unchanged. |
| Half-life | Terminal elimination half-life: 13-20 hours (oral micronized); 36-48 hours (transdermal). Clinical context: supports once-daily oral or twice-weekly transdermal dosing. |
| Protein binding | 97-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | Approximately 1-2 L/kg. Large Vd indicates extensive tissue distribution including reproductive tissues, breast, liver, and bone. |
| Bioavailability | Oral: 2-10% (due to first-pass hepatic metabolism); Transdermal: 5-10% (dose-dependent); Intramuscular: 100% (as estradiol valerate); Vaginal: 5-25% (mucosal absorption). |
| Onset of Action | Oral: 2-4 hours; Transdermal: 4-8 hours; Intramuscular (estradiol valerate): 24-48 hours; Vaginal: 30-60 minutes. |
| Duration of Action | Oral: 24 hours; Transdermal: 3-4 days (patch changed twice weekly); Intramuscular: 2-4 weeks; Vaginal: 12-24 hours for local effects. |
Oral: 1-2 mg daily; Transdermal: 0.025-0.1 mg/day applied twice weekly; Topical gel: 0.75-1.25 mg daily; Vaginal: 0.5-2 mg daily depending on formulation.
| Dosage form | SYSTEM |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, use with caution and monitor for fluid retention. |
| Liver impairment | Contraindicated in severe hepatic dysfunction (Child-Pugh class C); in mild-moderate impairment (Child-Pugh A-B), reduce dose by 50% and monitor transaminases. |
| Pediatric use | Not indicated for use in pediatric patients; for pubertal induction in Turner syndrome: starting dose 0.25 mg oral daily, titrate over 2-4 years to adult dose. |
| Geriatric use | Initiate at lowest effective dose; use short-term if possible due to increased risk of thromboembolism, stroke, and cognitive decline in women aged ≥65 years. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Inducers of CYP450 enzymes (eg carbamazepine) may decrease estrogen levels Increases risk of thromboembolic disorders and endometrial cancer.
| Breastfeeding | Estradiol is excreted into human breast milk in small amounts (M/P ratio approximately 0.04-0.17). Use during lactation may reduce milk production and quality. Breastfeeding is generally not recommended during estradiol therapy, especially in high doses. If used, monitor infant for potential estrogenic effects such as breast enlargement or vaginal discharge. |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: Estradiol exposure is associated with an increased risk of congenital anomalies, including cardiovascular and limb defects. Second and third trimesters: Use is contraindicated due to risks of feminization of male fetus, urogenital tract abnormalities, and potential long-term reproductive effects. There is no indication for use in pregnant women. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risk of endometrial cancer in women with intact uterus; use with progestin, if uterus intact. Increased risk of stroke, DVT, PE, MI, and breast cancer.
| Common Effects | osteoporosis prevention |
| Serious Effects |
["Known or suspected pregnancy","Undiagnosed abnormal genital bleeding","Known or suspected breast cancer (except selected advanced cases)","Known or suspected estrogen-dependent neoplasia","Active DVT/PE or history of these conditions","Arterial thromboembolic disease (e.g., stroke, MI)","Known hypersensitivity to estradiol or components","Hepatic impairment or disease"]
| Precautions | ["Cardiovascular disorders (stroke, MI, thromboembolism)","Malignant neoplasms (endometrial, breast, ovarian)","Gallbladder disease","Hypercalcemia (in breast cancer patients)","Retinal vascular thrombosis","Fluid retention (aggravate asthma, epilepsy, migraine, renal/cardiac dysfunction)","Hypothyroidism (may need increased thyroid replacement)","Hereditary angioedema"] |
Loading safety data…
| Fetal Monitoring | No routine monitoring indicated as estradiol is contraindicated in pregnancy. However, if inadvertent exposure occurs, fetal ultrasound and cardiac assessment may be considered. For lactating mothers, monitor infant growth and development. General monitoring: bone mineral density (if long-term use), uterine ultrasound, and endometrium biopsy if breakthrough bleeding occurs. |
| Fertility Effects | Estradiol can inhibit ovulation by suppressing gonadotropin secretion, thus acting as a contraceptive in some contexts. Used adjunctively in assisted reproductive technology to support endometrial growth. In males, estrogen excess can impair spermatogenesis and fertility. Discontinuation may restore normal fertility. |
| Food/Dietary | Grapefruit juice may increase estradiol levels by inhibiting CYP3A4 metabolism. St. John's Wort may reduce estradiol efficacy via CYP3A4 induction. Avoid alcohol, as it may increase estrogen levels and risk of liver toxicity. In patients with hypertriglyceridemia, oral estradiol may exacerbate condition; recommend transdermal route. |
| Clinical Pearls | Estradiol is the most potent endogenous estrogen; use lowest effective dose for shortest duration. In menopausal hormone therapy, do not use oral estradiol in patients with hypertriglyceridemia due to increased VLDL synthesis; transdermal route bypasses first-pass metabolism. Estradiol increases risk of venous thromboembolism, stroke, and endometrial cancer (when unopposed by progestin in uterus-intact women). For transgender women, titrate to target serum estradiol levels (100-200 pg/mL) and monitor for hyperprolactinemia and thromboembolic events. Avoid in patients with estrogen-sensitive malignancies (breast, endometrial). |
| Patient Advice | Take estradiol exactly as prescribed; do not increase dose or frequency. Report unusual vaginal bleeding, breast lumps, or jaundice immediately. · If you are a woman with a uterus, you must also take a progestin to protect against uterine cancer unless you have had a hysterectomy. · Stop smoking, as smoking increases the risk of blood clots and stroke while on estradiol. · Transdermal patches should be applied to clean, dry, non-hairy skin on the lower abdomen or buttocks; rotate sites to avoid irritation. · Store estradiol at room temperature away from moisture and heat. Do not use if the package seal is broken. |